Gene therapy of inherited immunodeficiencies

Bibliography

• Heissig B, Ohki Y, Sato Y, et al. A role for niches in hematopoietic cell development. Hematology 2005;10:247-53
   PubMed Web of Science ®Google Scholar
• Dornburg R. The history and principles of retroviral vectors. Front Biosci 2003;8:d818-35
   PubMed Web of Science ®Google Scholar
• Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-42
   PubMed Web of Science ®Google Scholar
• Fischer A, Le DF, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 2005;203:98-109
   PubMed Web of Science ®Google Scholar
• Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147-57
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63
   PubMed Web of Science ®Google Scholar
• White H, Thrasher A, Veys P, Kinnon C, Gaspar HB. Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur J Immunol 2000;30:732-7
   PubMed Web of Science ®Google Scholar
• Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8
   PubMed Web of Science ®Google Scholar
• Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968 – 1999. Lancet 2003;361:553-60
   PubMed Web of Science ®Google Scholar
• Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998;91:3646-53
   PubMed Web of Science ®Google Scholar
• Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-16
   PubMed Web of Science ®Google Scholar
• Bousso P, Wahn V, Douagi I, et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci USA 2000;97:274-8
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, De Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Le DF, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-93
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-7
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005;105:4255-7
   PubMed Web of Science ®Google Scholar
• Chinen J, Davis J, De Ravin SS, et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 2007;110:67-73
   PubMed Web of Science ®Google Scholar
• Hale LP, Buckley RH, Puck JM, Patel DD. Abnormal development of thymic dendritic and epithelial cells in human X-linked severe combined immunodeficiency. Clin Immunol 2004;110:63-70
   PubMed Web of Science ®Google Scholar
• Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency. Proceedings of the EBMT Satellite Workshop (Hamburg, March 2006). Clin Immunol 2007;123:139-47
   PubMed Web of Science ®Google Scholar
• Chaffee S, Mary A, Stiehm ER, et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992;89:1643-51
   PubMed Web of Science ®Google Scholar
• Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475-80
   PubMed Web of Science ®Google Scholar
• Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003;101:2563-9
   PubMed Web of Science ®Google Scholar
• Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995;270:470-5
   PubMed Web of Science ®Google Scholar
• Hoogerbrugge PM, van BV, Fischer A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996;3:179-83
   PubMed Web of Science ®Google Scholar
• Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995;1:1017-23
   PubMed Web of Science ®Google Scholar
• Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 2002;8:423-5
   PubMed Web of Science ®Google Scholar
• Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-3
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006;14:505-13
   PubMed Web of Science ®Google Scholar
• Candotti F, Kohn DB. Gene Therapy for adenosine deaminase deficiency in the USA. IVth Conference on Stem Cell Gene Therapy; 2007
   Google Scholar
• Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood 2007;109:503-6
   PubMed Web of Science ®Google Scholar
• Ariga T. Hematopoietic stem cell (HSC) gene therapy for two patients with adenosine deaminase (ADA) deficiency without cytoreductive conditioning; a suggestion for the optimal protocol for HSC gene therapy for ADA deficiency. IVth Conference on Stem Cell Gene Therapy; 2007
   Google Scholar
• Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood 2006;108:2979-88
   PubMed Web of Science ®Google Scholar
• Carbonaro DA, Jin X, Petersen D, et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther 2006;13:1110-20
   PubMed Web of Science ®Google Scholar
• Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78(4):635-44. Erratum in: Cell 1994;79(5):following page 922
   PubMed Web of Science ®Google Scholar
• Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006;117:725-38
   PubMed Web of Science ®Google Scholar
• Millard TH, Sharp SJ, Machesky LM. Signalling to actin assembly via the WASP (Wiskott-Aldrich syndrome protein)-family proteins and the Arp2/3 complex. Biochem J 2004;380:1-17
   PubMed Web of Science ®Google Scholar
• Proust A, Guillet B, Picard C, et al. Detection of 28 novel mutations in the Wiskott-Aldrich syndrome and X-linked thrombocytopenia based on multiplex PCR. Blood Cells Mol Dis 2007;39:102-6
   PubMed Web of Science ®Google Scholar
• Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001;27:313-7
   PubMed Web of Science ®Google Scholar
• Moulding DA, Blundell MP, Spiller DG, et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med 2007;204:2213-24
   PubMed Web of Science ®Google Scholar
• Candotti F, Facchetti F, Blanzuoli L, et al. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying ‘null’ mutations. Gene Ther 1999;6:1170-4
   PubMed Web of Science ®Google Scholar
• Wada T, Jagadeesh GJ, Nelson DL, Candotti F. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther 2002;13:1039-46
   PubMed Web of Science ®Google Scholar
• Strom TS, Turner SJ, Andreansky S, et al. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood 2003;102:3108-16
   PubMed Web of Science ®Google Scholar
• Strom TS, Gabbard W, Kelly PF, Cunningham JM, Nienhuis AW. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein. Gene Ther 2003;10:803-9
   PubMed Web of Science ®Google Scholar
• Klein C, Nguyen D, Liu CH, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 2003;101:2159-66
   PubMed Web of Science ®Google Scholar
• Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther 2006;8:390-5
   PubMed Web of Science ®Google Scholar
• Dupre L, Trifari S, Follenzi A, et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther 2004;10:903-15
   PubMed Web of Science ®Google Scholar
• Dupre L, Marangoni F, Scaramuzza S, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 2006;17:303-13
   PubMed Web of Science ®Google Scholar
• Charrier S, Stockholm D, Seye K, et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 2005;12:597-606
   PubMed Web of Science ®Google Scholar
• Charrier S, Dupre L, Scaramuzza S, et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2007;14:415-28
   PubMed Web of Science ®Google Scholar
• Ariga T, Kondoh T, Yamaguchi K, et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J Immunol 2001;166:5245-9
   PubMed Web of Science ®Google Scholar
• Wada T, Schurman SH, Otsu M, et al. Somatic mosaicism in Wiskott – Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci USA 2001;98:8697-702
   PubMed Web of Science ®Google Scholar
• Wengler G, Gorlin JB, Williamson JM, Rosen FS, Bing DH. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood 1995;85:2471-7
   PubMed Web of Science ®Google Scholar
• Martin F, Toscano MG, Blundell M, et al. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 2005;12:715-23
   PubMed Web of Science ®Google Scholar
• Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther 2008;8:181-90
   PubMed Web of Science ®Google Scholar
• Babior BM. NADPH oxidase. Curr Opin Immunol 2004;16:42-7
   PubMed Web of Science ®Google Scholar
• Segal AW. How neutrophils kill microbes. Ann Rev Immunol 2005;23:197-223
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69
   PubMed Web of Science ®Google Scholar
• Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985 – 2000. Blood 2002;100:4344-50
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001;344:881-8
   PubMed Web of Science ®Google Scholar
• Woodman RC, Newburger PE, Anklesaria P, et al. A new X-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. Blood 1995;85:231-41
   PubMed Web of Science ®Google Scholar
• Malech HL, Choi U, Brenner S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn J Infect Dis 2004;57:S27-8
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9
   PubMed Web of Science ®Google Scholar
• European Society of Gene Therapy (ESGT). One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease: a position statement from the European Society of Gene Therapy (ESGT). J Gene Med 2006;8:1435
   Google Scholar
• Grez M, Hoelzer D, Ott MG. Gene therapy of chronic granulomatous disease: results and perspectives. 4th Annual Conference of British Society for Gene Therapy; 2007
   Google Scholar
• Grez M, Ott M, Stein S, et al. PhaseI/II gene therapy study for X-CGD: results, lessons and perspectives. IVth Conference on Stem Cell Gene Therapy; 2007
   Google Scholar
• Hacein-Bey-Abina S, von KC, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6
   PubMed Web of Science ®Google Scholar
• Deichmann A, Hacein-Bey-Abina S, Schmidt M, et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007;117:2225-32
   PubMed Web of Science ®Google Scholar
• Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007;117:2241-9
   PubMed Web of Science ®Google Scholar
• Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-9
   PubMed Web of Science ®Google Scholar
• Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003;300:1749-51
   PubMed Web of Science ®Google Scholar
• Bushman FD. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell 2003;115:135-8
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Gaspar HB, Baum C, et al. X-SCID transgene leukaemogenicity. Nature 2006;443:E5-6. Published online 20 September 2006, doi:10.1038/nature05219
   Web of Science ®Google Scholar
• Pike-Overzet K, de RD, Weerkamp F, et al. Gene therapy: is IL2RG oncogenic in T-cell development? Nature 2006;443:E5. Published online 20 September 2006, doi:10.1038/nature05218
   PubMed Web of Science ®Google Scholar
• Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 1991;88:4367-71
   PubMed Web of Science ®Google Scholar
• Pike-Overzet K, de RD, Weerkamp F, et al. Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 2007;21:754-63
   PubMed Web of Science ®Google Scholar
• Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004;303:333
   PubMed Web of Science ®Google Scholar
• Woods NB, Bottero V, Schmidt M, von KC, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature 2006;440:1123
   PubMed Web of Science ®Google Scholar
• Calmels B, Ferguson C, Laukkanen MO, et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005;106:2530-3
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-96
   PubMed Web of Science ®Google Scholar
• Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 2006;103:11730-5
   PubMed Web of Science ®Google Scholar
• Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006;108:2545-53
   PubMed Web of Science ®Google Scholar
• Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci USA 2006;103:16406-11
   PubMed Web of Science ®Google Scholar
• Adjali O, Marodon G, Steinberg M, et al. In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer. J Clin Invest 2005;115:2287-95
   PubMed Web of Science ®Google Scholar
• Yates F, Malassis-Seris M, Stockholm D, et al. Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency. Blood 2002;100:3942-9
   PubMed Web of Science ®Google Scholar
• Lagresle-Peyrou C, Yates F, Malassis-Seris M, et al. Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity. Blood 2006;107:63-72
   PubMed Web of Science ®Google Scholar
• Yu SF, von RT, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986;83:3194-8
   PubMed Web of Science ®Google Scholar
• Thornhill SI, Schambach A, Howe SJ, et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008
   PubMedGoogle Scholar
• Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7
   PubMed Web of Science ®Google Scholar
• Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12:348-53
   PubMed Web of Science ®Google Scholar
• Papapetrou EP, Ziros PG, Micheva ID, Alt FW, Mulligan RC. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther 2006;13:40-51
   PubMed Web of Science ®Google Scholar
• Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol 2001;21:3926-34
   PubMed Web of Science ®Google Scholar
• Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435:646-51
   PubMed Web of Science ®Google Scholar
• Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;257:99-103
   PubMed Web of Science ®Google Scholar
• Davis BM, Koc ON, Gerson SL. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 2000;95:3078-84
   PubMed Web of Science ®Google Scholar
• Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998;4:1136-43
   PubMed Web of Science ®Google Scholar
• Rappa G, Anzanello F, Alexeyev M, Fodstad O, Lorico A. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease. Eur J Haematol 2007;78:440-8
   PubMed Web of Science ®Google Scholar